0001144204-18-004781.txt : 20180131 0001144204-18-004781.hdr.sgml : 20180131 20180131095934 ACCESSION NUMBER: 0001144204-18-004781 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180129 FILED AS OF DATE: 20180131 DATE AS OF CHANGE: 20180131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Masterson Nola E CENTRAL INDEX KEY: 0001305231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 18561284 MAIL ADDRESS: STREET 1: 768 WEST CALIFORNIA WAY CITY: WOODSIDE STATE: CA ZIP: 94062 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 4 1 tv484342_4.xml OWNERSHIP DOCUMENT X0306 4 2018-01-29 1 0000897075 REPROS THERAPEUTICS INC. RPRX 0001305231 Masterson Nola E 768 WEST CALIFORNIA WAY WOODSIDE CA 94062 1 0 0 0 Common Stock 2018-01-29 4 U 0 12221 0.67 D 27779 D Common Stock 2018-01-31 4 D 0 27779 0.67 D 0 D Stock Option 0.32 2018-01-31 4 D 0 5000 D 2027-09-15 Common Stock 5000 0 D Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value $0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2) (continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) $0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor. The Shares subject to this option were fully vested immediately prior to the Effective Time. /s/ Katherine A. Anderson, Attorney-in-fact 2018-01-31